Formulation Development and Evaluation of Mouth Dissolving Tablets of Loratadine
AbstractDifficulty in swallowing (dysphagia) is common among all age groups, especially in elderly and pediatrics.
Mouth dissolving tablets constitute an innovative dosage forms that overcome the problems of swallowing
and provides a quick onset of action. The purpose of this study was to formulate and evaluate mouth
dissolving tablet of loratadine using a special preparation technology (pharmaburst Technology) with a super
disintegrating agent (Croscarmellose sodium). Tablets were prepared by direct compression technique. The
granules were evaluated for angle of repose, bulk density, tapped density, bulkiness, compressibility index
and hausners ratio. The tablets were evaluated for hardness, thickness, uniformity of weight, friability, wetting
time, water absorption ratio, disintegration time and drug content. In vitro release studies were performed
using USP-II (paddle method) in 900ml of pH 1.2 at 50rpm. The physical properties of the prepared tablets
did not show any significant variations and were found to have good physical integrity. Tablets prepared with
pharmaburst B2 and Croscarmellose sodium showed a lesser disintegration time and wetting time of 27±0.10
and 38±0.13 seconds respectively. The best formulations were subjected to stability studies at 40ºC/75% RH
for 60 days.
Key words: Loratadine; pharmaburst B2; croscarmellose sodium; mouth dissolving tablets; direct
Stamford Journal of Pharmaceutical Sciences Vol.2(2) 2009: 59-65
Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.